$VCYT

Veracyte Inc

  • NASDAQ
  • Health Technology
  • Biotechnology
  • Health Care and Social Assistance
  • Medical Laboratories

PRICE

$18.89 -

Extented Hours

VOLUME

1,034,701

DAY RANGE

17.28 - 18.94

52 WEEK

14.85 - 54.13

Join Discuss about VCYT with like-minded investors

profile
@dros #droscrew
recently

+Initiations 1/7: $ACVA $AER $BILL $CMPO $CSTL $DMTK $DNA $ET $GDRX $IMRX $NRDY $NTLA $OCX $PL $PSTX $RBOT $SSNC $UPWK $VCYT

90 Replies 15 👍 15 🔥

Key Metrics

Market Cap

1.35 B

Beta

2.28

Avg. Volume

1.25 M

Shares Outstanding

71.45 M

Yield

0%

Public Float

0

Next Earnings Date

2022-07-28

Next Dividend Date

Company Information

Veracyte is a global genomic diagnostics company that improves patient care by providing answers to clinical questions, informing diagnosis and treatment decisions throughout the patient journey in cancer and other diseases. The company's growing menu of genomic tests leverage advances in genomic science and technology, enabling patients to avoid risky, costly diagnostic procedures and quicken time to appropriate treatment. The company's tests in lung cancer, prostate cancer, breast cancer, thyroid cancer, bladder cancer and idiopathic pulmonary fibrosis are available to patients and its lymphoma subtyping and renal cancer tests are in development. With Veracyte's exclusive global license to a best-in-class diagnostics instrument platform, the company is positioned to deliver its tests to patients worldwide. Veracyte is based in South San Francisco, California.

CEO: Bonnie Anderson

Website:

HQ: 6000 Shoreline Ct Ste 300 South San Francisco, 94080-7606 California

Related News